AV457

AV457 is a potent and selective mTOR inhibitor with an IC50 value of 0.54 µM. AV457 inhibits cyst growth in polycystic kidney disease (PKD) organoids. AV457 decreases the protein expression of P-s6, P-p70s6 and don’t decreases the protein expression of P-AKT[1].

Product Specifications

CAS Number

[2713387-11-0]

UNSPSC

12352005

Target

MTOR

Related Pathways

PI3K/Akt/mTOR

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Smiles

O=C([C@@]1(O)[C@@H](CC[C@@H](C[C@@H](/C(C)=C/C=C/C=C/[C@H](C[C@@H](C)C([C@@H]([C@@H](/C(C)=C/[C@H]2C)O)OC)=O)C)NS(CCOCCOC)(=O)=O)O1)C)C(N3CCCC[C@H]3C(O[C@@H](CC2=O)[C@@H](C[C@H]4C[C@H]([C@H](O)CC4)OC)C)=O)=O

Molecular Formula

C55H88N2O16S

Molecular Weight

1065.36

References & Citations

[1]Gulieva RE, et al. A novel rapalog shows improved safety vs. efficacy in a human organoid model of polycystic kidney disease. Stem Cell Reports. 2025 Jan 9:102395.